Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing 

MENLO PARK, CA – January 5, 2021 – Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today the closing of a non-brokered private placement financing, raising gross proceeds of $9.1 million. The financing was led by Global Health Investment Advisors. The Company sold 628,930 shares of Series A Preferred Stock and 808,877 shares of Common Stock at a purchase price of $6.36 per share (“Offering”). 

The Company intends to use the net proceeds of the Offering for general working capital purposes and the development of REVTx-99 and REVDx-501. REVTx-99 is being developed as a therapy for the treatment of a wide range of respiratory viral infections, including COVID-19. REVDx-501 is a diagnostic being developed to test for upper respiratory viral infections including COVID-19. The funding will also facilitate investigation into additional indications for REVTx-99, along with general and administrative operations. 

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For more information on Revelation, please visit www.RevBiosciences.com

About Revelation Biosciences Inc. 

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx‑99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS‑CoV‑2 infection. An expansion of REVTx‑99 therapeutic indications is planned, targeting early treatment and prevention of respiratory viral infection such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx‑200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx‑501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type without the need for specialized instrumentation. For more information on Revelation, please visit www.RevBiosciences.com.

About Global Health Investment Advisors

Through its work as the investment manager for the Global Health Investment Fund and its partnership with AXA Investment Managers, Global Health Investment Advisors has pioneered impact investing in life science companies. The firm seeks attractive financial returns and works with companies to facilitate the introduction of innovative products worldwide, including low-income countries. Its portfolio companies have generated compelling exits and have saved and improved millions of lives. For more information, please visit www.globalhealthfunds.com. 

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. These risks include, but are not limited to, risks relating to: the timing, costs, conduct, and success of our development activities for REVTx-99 and expanded indications, REVTx-200, REVDx-501, or any other product candidates; the timing, costs, conduct and outcome of our other clinical studies, including the Phase 1  clinical study for REVTx-99; the anticipated treatment of future clinical data by the FDA, the EMA, or other regulatory authorities, including whether such data will be sufficient for approval; potential indications for which our product candidates may be developed; the potential impact that COVID-19 may have on us, our suppliers, vendors, regulatory agencies, our employees, and the global economy as a whole; and the expected duration over which the Company’s balance will fund us. 

Company Contacts 

Sandra Vedrick

Vice President, Investor Relations & Human Resources

Revelation Biosciences Inc.

Email: svedrick@revbiosciences.com

and

Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences Inc.

Email: czygmont@revbiosciences.com